Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

339.31 -13.32 (-3.78%)
Streaming Delayed Price Updated: 1:27 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 4, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Praxis Precision Medicine's Earnings ↗
 
Via Benzinga
News headline image
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures ↗
Praxis Precision Medicines stock fluctuated after reporting mixed results for their drug vormatrigine in treating focal onset seizures. 
Via Benzinga
News headline image
Praxis (PRAX) Q2 Loss Widens 90% ↗
Via The Motley Fool
News headline image
Praxis Precision Medicines (NASDAQ:PRAX) Posts Q2 2025 Results with Strong Clinical Progress on Vormatrigine ↗
Praxis Precision Medicines (PRAX) reports Q2 2025 results, highlighting strong clinical data for epilepsy drug vormatrigine with 56.3% seizure reduction. EPS beats estimates, stock rises pre-market. 
Via Chartmill
News headline image
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Participate in Upcoming Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside ↗
Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine. 
Via Benzinga
News headline image
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Assessing Praxis Precision Medicine: Insights From 8 Financial Analysts ↗
 
Via Benzinga
News headline image
Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings) ↗
 
Via Benzinga
News headline image
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Participate in Upcoming April Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.